Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Current strategies for melanoma monitoring, such as imaging techniques and serum biomarkers, often lack the sensitivity required to detect early recurrences. Liquid biopsies, including the analysis of circulating cell-free DNA (cfDNA), have emerged as clinically relevant strategies for non-invasive disease monitoring cancer. cfDNA fragmentomics, which investigates the fragmentation patterns of cfDNA, offers potential as a novel biomarker for tracking cancer progression ([1],[2]). This study aimed to characterize global cfDNA fragmentomics in a cohort of melanoma patients under clinical follow-up.
Source: EJC Skin Cancer
Authors: J.L. Villanueva-Cañas, D. Rizo-Potau, A. Fornies, M. Aguilar, C. Sanchez-Cardenas, C. Carrera, S. Puig, J. Malvehy, J.A. Puig-Butille
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409116705